Figure 4. miR-107 inhibition alleviates DEX-induced oxidative injury in osteoblasts. OB-6 cells (A–C) or primary human osteoblasts (G and H) with pre-miRNA-107 anti-sense lentivirus (antagomiR-107) or control anti-sense lentivirus (antagomiR-C), were treated with DEX (1 μM) or the vehicle control (“Veh”) for 12h, cellular superoxide contents (A and G), lipid peroxidation levels (B) and mitochondrial depolarization (JC-1 green fluorescence intensity, C and H) were tested. Expression of listed Nrf2 pathway genes in OB-6 cells and primary human osteoblasts, with antagomiR-107 or antagomiR-C, was shown (D, E, I and J), with NQO1 activity tested as well (F and J). Data were mean ± standard deviation (SD, n=5). * p<0.05 vs. “Veh” treatment in “antagomiR-C” cells (A–C, G and H). # p<0.05. vs. “DEX” treatment in “antagomiR-C” cells (A–C, G and H). * p<0.05 vs. “Pare” cells (E and F). Each experiment was repeated three times and similar results were obtained.